JWH-073
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
JWH-073 is a synthetic cannabinoid of the naphthoylindole class. It is the N-butyl homolog of JWH-018 — roughly half as potent but still substantially stronger than cannabis.[1] It activates cannabinoid receptors in the brain as a full agonist, with no ceiling on how strong the effect can get.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
THC, JWH-018, JWH-250 +1 moreTHC, JWH-018, JWH-250, cannabinoids (all CB1 agonists) show less
JWH-073 was synthesized by John W. Huffman around 1984 as one of over 400 cannabinoid research tools.[3] In early 2009 it replaced JWH-018 in "Spice" and "K2" blends after Germany banned JWH-018[4] — starting the cat-and-mouse reformulation pattern that defined the synthetic cannabinoid market. It is now permanently controlled in the United States and most Western countries.[5]
Subjective effects include euphoria, sedation, appetite enhancement, and pain suppression. The experience resembles cannabis compressed into a shorter window — low doses bring deep relaxation, but a narrow margin separates comfort from adverse territory, with anxiety and disorientation arriving quickly as the dose rises.[6] Rapid heartbeat, anxiety, paranoia, and at higher doses seizures or acute psychosis are documented.[7]
JWH-073 produces physical and psychological dependence, and its toxicity profile is steeper than cannabis.[8][9] Full agonism means no ceiling — effects can escalate to seizures, heart emergencies, and multi-organ failure without the natural limit that Δ9-THC provides.[9] No controlled human study exists; all knowledge comes from animal models, case reports, and laboratory pharmacology.[10]
History[edit]
Discovery
John William Huffman synthesized JWH-073 at Clemson University around 1984 as part of a NIDA-funded project.[3] His laboratory produced over 400 cannabinoid compounds as research tools for mapping the endocannabinoid system. JWH-073 appeared in published structure-activity studies on naphthoylindoles[11][12] and was never intended for human use.
Market emergence
JWH-073 appeared in "Spice" and "K2" herbal blends in February 2009, substituted for JWH-018 after Germany banned that compound in late 2008.[4] This rapid substitution — one compound banned, another taking its place — defined the synthetic cannabinoid market for years.
Prohibition
The UK banned JWH-073 under a generic naphthoylindole definition around December 2009.[13] The US DEA temporarily scheduled it in March 2011 as an "imminent hazard to public safety",[14] then permanently in March 2012.[5] Australia and Canada followed in 2011.[13]
The "JWH" naming convention — a chemist's initials followed by a lab index number — became synonymous with the synthetic cannabinoid wave of the late 2000s and early 2010s. Huffman publicly called the recreational use of his research tools "a disaster." JWH-073's identity is inseparable from the "Spice" phenomenon: a period when dozens of research chemicals cycled through herbal blend products faster than regulators could schedule them.
Chemistry[edit]
Structure
JWH-073 belongs to the naphthoylindole class of synthetic cannabinoids.[15] The molecule connects an indole ring — carrying a four-carbon butyl chain — to a naphthalene ring through a carbonyl bridge, the structural feature responsible for binding to cannabinoid receptors.[16] Its molecular formula is C₂₃H₂₁NO (327.4 g/mol).
The four-carbon chain is one carbon shorter than the five-carbon chain in JWH-018. That single difference is why JWH-073 binds cannabinoid receptors roughly half as strongly.[11][12][16] JWH-073 has no stereocenters and exists as one molecular form.[15]
Pharmacology[edit]
Mechanism of action
JWH-073 is a full agonist at CB1 and CB2 cannabinoid receptors.[2][17] Unlike Δ9-THC — a partial agonist with a built-in ceiling — JWH-073 drives receptors to maximum activation. There is no natural stopping point.
CB1 activation triggers dopamine release in the brain's mesolimbic pathway, producing euphoria and reinforcing repeated use.[17] JWH-073 also suppresses memory formation in the hippocampus by roughly 60% in laboratory settings.[18]
Pharmacokinetics
When smoked, onset is rapid. The body converts JWH-073 into metabolites through hydroxylation[2][19] — one partially blocks the parent compound's effects as it builds up,[2] another retains full activity.[2] A urinary marker is detectable 11–25 days after stopping,[20] and standard cannabis drug screens will not detect it.[21]
Neuroscience[edit]
Where it acts
JWH-073 activates CB1 receptors concentrated in the hippocampus, neocortex, basal ganglia, and cerebellum. Normally, the brain's own cannabinoid molecules are released on demand to fine-tune specific synapses. JWH-073 floods these receptors indiscriminately — suppressing memory circuits, stimulating reward circuits, and broadly disrupting cortical activity.[18][17]
Why it matters
The endocannabinoid system acts as a thermostat for synaptic signaling. JWH-073 overrides that thermostat, activating receptors to maximum regardless of what any circuit needs.[17] This explains the dose response: gentle sedation at lower exposures, agitation, seizures, and psychosis when receptors are saturated.
In mice, JWH-073 disrupts brain wave activity across multiple frequency bands for at least 24 hours after behavioral effects have cleared.[18] Whether this persists longer or accumulates with repeated use is unknown. No human neuroimaging studies have been conducted; the neural correlates of its subjective effects are entirely inferred from animal work. Whether the neutral-antagonist metabolite M4[2] contributes to the rapid subjective offset also remains untested.
Subjective Effects[edit]
JWH-073 produces a cannabis-like experience compressed into a shorter window. At lower amounts, the dominant feeling is warm sedation — relaxation, appetite stimulation, and mild euphoria. As the dose rises, effects push past the ceiling cannabis imposes, and relaxation gives way to anxiety and disorientation with little warning.
Compared to JWH-018, JWH-073 is roughly half as potent and reportedly shorter-acting. Compared to Δ9-THC, it shares the same broad character — altered time perception, euphoria, and appetite enhancement — but with a narrower gap between comfortable and adverse. The absence of CBD removes a factor that may moderate cannabis psychosis risk.
Effect Grid
Clear cannabis-like euphoria and sedation dominate. Appetite enhancement is pronounced, pain suppression becomes noticeable, and time alteration produces a subjective slowing of temporal perception. Emotional enhancement colors the experience — music, food, and social interaction may feel more engaging.
Physical effects are evident: bodily heaviness, motor control impairment, dry mouth, and dehydration sensation. Heart rate elevation is common. Cognitive function is reduced — thought deceleration, analysis suppression, and mild memory impairment are typical. Some users experience anxiety or paranoia at this level, particularly in unfamiliar settings.
Total duration is approximately 1–2 hours. Functional impairment is significant enough to preclude driving or complex tasks. Product variability in herbal blends makes consistent dosing at this tier unreliable.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Taste enhancement · Color enhancement · Auditory enhancement · Depth perception distortion · Visual haze / noise · Geometry
Depth perception distortion · Visual haze / noise · Geometry
Dehydration sensation · Bodily heaviness · Abnormal heartbeat · Dizziness · Heart rate perception changes · Physical fatigue · Appetite enhancement · Spontaneous body sensations · Pain suppression · Muscle relaxation · Tactile euphoria · Headache · Laughter fits · Pupil dilation · Insomnia · Nausea · Restlessness · Trembling · Vomiting
Heart rate perception changes · Physical fatigue · Appetite enhancement · Spontaneous body sensations · Pain suppression · Muscle relaxation · Tactile euphoria · Headache · Laughter fits · Pupil dilation · Insomnia · Nausea · Restlessness · Trembling · Vomiting
Analysis suppression · Focus suppression · Cognitive fatigue · Confusion · Memory fragmentation · Thought connectivity · Aesthetic enhancement · Immersion enhancement · Novelty enhancement · Thought disorganization · Thought loops · Humor enhancement · Conceptual thinking · Creativity enhancement · Delusions
Confusion · Memory fragmentation · Thought connectivity · Aesthetic enhancement · Immersion enhancement · Novelty enhancement · Thought disorganization · Thought loops · Humor enhancement · Conceptual thinking · Creativity enhancement
Dysphoria · Irritability
Derealization
Timeline
First perceptible effects within seconds to minutes of inhalation — a subtle shift in headspace and mild warmth as CB1 engagement begins.
Rapid intensification of euphoria, body high, and cognitive shift. Effects build noticeably faster than cannabis due to high CB1 affinity.
Maximum intensity — euphoria or dysphoria, sedation, appetite enhancement, cognitive impairment, and time alteration. Adverse effects (tachycardia, anxiety, paranoia) are most likely during this phase.
Gradual return toward baseline. Motor and cognitive impairment may lag behind subjective recovery. The M4 neutral antagonist metabolite may contribute to subjective offset.
Residual sedation, mild appetite effects, and subtle cognitive cloudiness. EEG perturbation documented persisting at 24 hours in mice, suggesting subclinical neural effects beyond subjective recovery.
⚠ Do not drive or operate machinery for at least 4 hours after use — subclinical cognitive impairment may persist beyond subjective recovery.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- THC · JWH-018 · JWH-250
Toxicity
No lethal dose has been established for JWH-073 in any species. This is a critical evidence gap for a compound with documented human exposure.
Acute toxicity
JWH-073's full agonist status means effects can escalate without a ceiling,[2] producing a steeper dose-toxicity curve than cannabis.[22] Case reports document seizures, rapid or dangerously slow heartbeat, heart attacks, acute psychosis, muscle breakdown, kidney injury, and multi-organ failure.[6][23][24] A review of roughly 4,000 synthetic cannabinoid cases found at least 26 deaths across the class.[9]
The acute toxicity of JWH-073 should be considered moderate to high. Case reports document seizures, heart emergencies, psychosis, and multi-organ failure. Most presentations are self-limiting, but severe outcomes occur unpredictably.
Heart and circulation
Rapid heartbeat is the most common adverse effect, appearing in 37–77% of synthetic cannabinoid emergency presentations.[9] Heart rate can shift from dangerously fast to dangerously slow.[23] One case documented a heart attack, bleeding in the brain, and reversible heart muscle damage.[24]
Cell toxicity
JWH-073 damaged cell membranes and caused DNA damage in mouth, breast, and liver cell lines at high concentrations in laboratory tests.[25] These concentrations exceeded expected blood levels, though direct tissue exposure during smoking may approach harmful thresholds.[25]
Psychological risks
JWH-073 carries a higher psychosis risk than cannabis.[22] Three factors converge: full CB1 agonism produces greater receptor activation than cannabis, the higher potency means smaller doses achieve equivalent exposure, and no CBD is present to moderate the effect.[22]
Case reports document acute psychosis with paranoia, delusions, hallucinations, and severe agitation.[6][7] One fatal case involved psychiatric breakdown and self-inflicted lethal injury.[26] Psychotic episodes occur more frequently in inexperienced users and those with pre-existing psychiatric vulnerability.[22]
Tolerance and dependence
Tolerance develops through CB1 receptor desensitization — the receptor becomes less responsive, and fewer copies remain on cell surfaces. Full agonists drive this process faster than partial agonists like Δ9-THC.[27][2] Cross-tolerance exists with all cannabinoids including THC.
Physical and psychological dependence are documented.[8][28] Withdrawal resembles cannabis withdrawal but may be more severe.[9] Benzodiazepines and antipsychotics have been used for symptom relief.[8]
Drug interactions
JWH-073 and JWH-018 together produce synergistic enhancement of cannabis-like effects at multiple dose ratios[29] — directly relevant to Spice/K2 products, which often contain multiple synthetic cannabinoids in unknown ratios. Sub-threshold doses of JWH-073 combined with JWH-250 synergistically impair motor function and boost dopamine release.[17]
Liver enzyme inhibitors (such as fluconazole or amiodarone) could slow JWH-073's breakdown and increase exposure; enzyme inducers (such as rifampin) could accelerate clearance.inferred No published data exist for interactions with stimulants or psychedelics, though combined dopamine activation from cocaine and JWH-073 would plausibly compound cardiovascular strain.
Contraindications
- History of psychosis or schizophrenia (absolute): full CB1 agonism markedly elevates the risk of triggering acute psychotic episodes.[22] No CBD is present to moderate this risk.
- Heart conditions (absolute): documented rapid and dangerously slow heart rates, heart attacks, and reversible heart muscle damage.[23][24]
- Concurrent stimulant use (relative): combined dopamine and epinephrine activation may compound cardiovascular strain.inferred
- Adolescent or young adult use (relative): younger users are disproportionately represented in severe adverse outcome reports.[7]
- Seizure disorder (relative): JWH-073 lowers the seizure threshold in animal models,[17] and seizures are documented in human cases.[6]
- Pregnancy and breastfeeding (absolute): no reproductive toxicity data exist. Given the high CB1 affinity and full agonist status, exposure during development cannot be considered safe.safety citation needed
Harm Reduction[edit]
Forms & Identification
JWH-073 almost exclusively appears as a component of herbal smoking blends — dried plant material sprayed with a synthetic cannabinoid solution. Labeling is unreliable: identity, concentration, and number of active compounds vary between brands, batches, and even portions of the same packet. Uneven spraying means one pinch may deliver a trivial dose while the next delivers a dangerous one.
Reagent testing can confirm the presence of a synthetic cannabinoid but cannot identify the specific compound or quantify the dose in a given sample.
Guidelines
- Test any product with available reagent kits before use. A positive result confirms a synthetic cannabinoid class but not identity or dose.
- Start with the smallest possible amount — a single shallow inhalation — and wait at least 15–20 minutes before considering more. The distance between a comfortable experience and an emergency is very short.
- Use only in the presence of a sober companion who knows what was consumed and can call for help.
- Avoid redosing within the same session. Acute effects from the previous dose may not have fully manifested.
- Eat a light meal beforehand and stay hydrated. Avoid alcohol, which compounds sedation and impairs judgment.
- Do not drive or operate machinery. Cognitive and motor impairment outlasts subjective effects.
Set & Setting
The steep dose curve and unpredictable product composition make set and setting unusually important with JWH-073. A calm, familiar environment with a sober companion present is strongly recommended. Anyone with a history of anxiety, panic attacks, or psychotic episodes faces substantially elevated risk and should consider abstinence.
Aftercare & integration. After acute effects resolve, residual cognitive dulling and low mood may persist for several hours to a day. Prioritize sleep, light nutrition, and gentle activity. Avoid any cannabinoid — synthetic or natural — for at least several days to allow CB1 recovery.
If the experience involved significant anxiety, paranoia, or psychotic symptoms, discuss it with a trusted person or a mental health professional. Recurring intrusive thoughts, persistent anxiety, or lingering perceptual disturbances after use warrant professional evaluation.
Recovery & Support
Daily synthetic cannabinoid use can produce physical and psychological dependence. Withdrawal may include irritability, insomnia, reduced appetite, anxiety, and cravings — resembling cannabis withdrawal but potentially more intense.[9] Medical supervision is advisable for anyone with a sustained daily habit, as some cases have required benzodiazepine or antipsychotic support.[8]
Peer support groups, addiction counselors, and substance use helplines can provide ongoing guidance. Substituting natural cannabis for synthetic cannabinoids during tapering has been reported by some users,[28] though this should be discussed with a healthcare provider rather than managed independently.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety or mild nausea is common and typically self-limiting. Seek immediate help if any of the following occur: seizures or uncontrollable muscle jerking, chest pain or irregular heartbeat, loss of consciousness or unresponsiveness, severe confusion with inability to recognize surroundings, self-harming behavior or expressed intent to self-harm, vomiting that does not stop.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. Do not restrain a seizing person — move objects away to prevent injury and let the seizure run its course.
- 4. Keep the person calm and in a quiet environment. Reduce stimulation.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance ("synthetic cannabinoid" or the product name), the amount if known, the time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
No reversal agent exists for synthetic cannabinoid toxicity. Treatment is supportive.
Legal Status[edit]
JWH-073 is a controlled substance in all major Western jurisdictions, prohibited as part of the regulatory response to synthetic cannabinoids appearing in "Spice" and "K2" products beginning in 2008–2009.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporarily placed March 1, 2011 as "imminent hazard to public safety";[14] permanently scheduled March 2012[5] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Banned under generic 3-(1-naphthoyl)indole definition, approximately December 2009[13] |
| Australia | Schedule 9 — Prohibited substance (Poisons Standard) | Effective July 8, 2011[13] |
| Canada | Controlled substance (Controlled Drugs and Substances Act) | Listed explicitly by compound name[13] |
| European Union | Varies by member state | No EU-wide Council Decision identified for JWH-073 specifically. Monitored by EMCDDA; reported by Austria July 2010. Individual member states addressed scheduling under national legislation. |
Analog act considerations
In jurisdictions with structural analog legislation — such as the US Federal Analogue Act — structural analogs of JWH-073 may be treated as controlled substances when intended for human consumption. Permanent scheduling of JWH-073 makes this mostly irrelevant for this compound, but it applies to novel naphthoylindole derivatives not yet individually scheduled.
Legal status varies by jurisdiction and changes frequently. This information is not legal advice.
references
- [1]
- [2] ^abcdefghBrents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity — Biochemical Pharmacology doi:10.1016/j.bcp.2012.01.004
- [3]
- [4] ^abDresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds — Journal of Mass Spectrometry doi:10.1002/jms.1811
- [5]
- [6] ^abcdSimmons J, Cookman L, Kang C, Skinner C (2011) Three cases of spice exposure — Clinical Toxicology doi:10.3109/15563650.2011.584316